Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Institute of Medical Physics and Biophysics, Charitéplatz 1, 10117, Berlin, Germany.
Department for Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Straße 65, 88397, Biberach an der Riss, Germany.
Angew Chem Int Ed Engl. 2018 Mar 1;57(10):2580-2585. doi: 10.1002/anie.201708764. Epub 2018 Feb 2.
The cannabinoid CB1 receptor (CB1R) is an abundant metabotropic G-protein-coupled receptor that has been difficult to address therapeutically because of CNS side effects exerted by orthosteric drug candidates. Recent efforts have focused on developing allosteric modulators that target CB1R. Compounds from the recently discovered class of mixed agonistic and positive allosteric modulators (Ago-PAMs) based on 2-phenylindoles have shown promising functional and binding properties as CB1R ligands. Here, we identify binding modes of both the CP 55,940 agonist and GAT228, a 2-phenylindole allosteric modulator, by using our metadynamics simulation protocol, and quantify their affinity and cooperativity by atomistic simulations. We demonstrate the involvement of multiple adjunct binding sites in the Ago-PAM characteristics of the 2-phenylindole modulators and explain their ability to compete with orthosteric agonists at higher concentrations. We validate these results experimentally by showing the contribution of multiple sites on the allosteric binding of ZCZ011, another homologous member of the class, together with the orthosteric agonist.
大麻素 CB1 受体 (CB1R) 是一种丰富的代谢型 G 蛋白偶联受体,由于正构药物候选物对中枢神经系统的副作用,其治疗一直具有挑战性。最近的研究重点是开发针对 CB1R 的变构调节剂。基于 2-苯基吲哚的最近发现的混合激动剂和正变构调节剂 (Ago-PAMs) 类别的化合物已显示出作为 CB1R 配体具有有前途的功能和结合特性。在这里,我们通过使用我们的元动力学模拟方案来确定 CP 55,940 激动剂和 GAT228(一种 2-苯基吲哚变构调节剂)的结合模式,并通过原子模拟量化它们的亲和力和协同性。我们证明了多个附加结合位点参与了 2-苯基吲哚调节剂的 Ago-PAM 特性,并解释了它们在较高浓度下与正构激动剂竞争的能力。我们通过显示另一个同源类别的成员 ZCZ011 的变构结合的多个位点的贡献,以及与正构激动剂一起,实验验证了这些结果。